<DOC>
	<DOCNO>NCT01173120</DOCNO>
	<brief_summary>The purpose study determine safety acceptability device use place traditional syrinx abatacept self-injection .</brief_summary>
	<brief_title>Methotrexate - Inadequate Response Device Sub-Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men woman , age â‰¥ 18 Participants consider methotrexate inadequate responder ( MTXIR ) 10 swollen joint ( 66 joint count ) 12 tender joint ( 68 joint count ) Participants enrol main MTXIR study treat open label abatacept least 3 month long term period Participants fail one multiple antitumor necrosis factor ( TNF ) therapies Participants meet diagnostic criterion rheumatic disease ( e.g. , lupus erythematosus ) Participants active vasculitis major organ system ( except subcutaneous rheumatoid nodule ) Participants severe chronic recurrent bacterial infection Participants receive treatment rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>